Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Zeinab Y Al SubehDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan.ORCID 0000-0001-9051-4969
Herma C PierreDepartment of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina 27402, United States.ORCID 0000-0002-3900-8099
Cedric J PearceMycosynthetix, Inc., Hillsborough, North Carolina 27278, United States.
Mark W GrinstaffDepartments of Biomedical Engineering and Chemistry, Boston University, Boston, Massachusetts 02215, United States.ORCID 0000-0002-5453-3668
Aaron H ColbyDepartments of Biomedical Engineering and Chemistry, Boston University, Boston, Massachusetts 02215, United States.ORCID 0000-0001-7161-821X
Kebin LiuDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia 30912, United States.ORCID 0000-0003-1965-7240
Nicholas H OberliesDepartment of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina 27402, United States.ORCID 0000-0002-0354-8464
Funding
Project 3:Isolation Chemistry of Filamentous Fungi and Biological EvaluationP01CA125066 · NCI · OHIO STATE UNIVERSITY · PI JIMMY ORJALA · 2007 to 2026
$27.2M
OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADINGFOR TREATING MESOTHELIOMAR01CA232056 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI COLSON, YOLONDA L, GRINSTAFF, MARK W. · 2019 to 2023
$2.7M
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCER01CA227433 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI COLSON, YOLONDA L, GRINSTAFF, MARK W. · 2018 to 2022
$2.7M
SUPERHYDROPHOBIC DRUG LOADED BUTTRESSES FOR PREVENTION OF LUNGTUMOR RECURRENCER01CA232708 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI COLSON, YOLONDA L, GRINSTAFF, MARK W. · 2019 to 2023
$2.2M
Treating Peritoneal Malignancies with Paclitaxel-Loaded Expansile NanoparticlesR44CA189215 · NCI · IONIC PHARMACEUTICALS · PI COLBY, AARON HENRY · 2019 to 2020
$2.0M
Predoctoral Training: Innovative Technologies for Natural Products and Integrative Medicine ResearchT32AT008938 · NCCIH · UNIVERSITY OF NORTH CAROLINA GREENSBORO · PI Nadja B Cech, Jonathan Rodi Chekan · 2016 to 2026
$1.6M
Fluorescent nanoparticles to improve resections of microscopic pancreatic tumorsR43CA224739 · NCI · IONIC PHARMACEUTICALS · PI COLBY, AARON HENRY · 2018 to 2018
$297k
Large Scale Synthesis and Biodistribution of Expansile NanoparticlesR43CA189215 · NCI · IONIC PHARMACEUTICALS · PI COLBY, AARON HENRY · 2014 to 2014
The fungal metabolite verticillin A is a potent and selective histone methyltransferase inhibitor. It regulates apoptosis, the cell cycle, and stress response, and displays potent activity in the suppression of tumor cell growth in several different in vivo models. Verticillin A sensitizes pancreatic cancer cells to anti-PD-1 immunotherapy by regulating PD-L1 expression. However, as with many natural products, delivery and systemic toxicity are challenges that must be overcome to advance their use as a chemotherapeutic. To both reduce systemic toxicity and improve delivery, we report a verticillin A-loaded surgical buttress, which is well-tolerated at a dose as high as 40 mg/kg. In contrast, free verticillin A administered systemically results in toxicity at a dose of 3 mg/kg. The verticillin A-loaded buttress suppresses tumor recurrence in vivo in a safe and dose-dependent manner against a highly aggressive and metastatic model of pancreatic cancer.
Indexed as
Neoplasm Recurrence, LocalPancreatic NeoplasmsAnimalsApoptosisCell Line, TumorDisease Models, AnimalFemaleHumansMiceXenograft Model Antitumor Assaysdrug-loaded surgical buttresshistone methyltransferaselocal drug deliverypancreatic cancerprolonged drug releaseverticillin A
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Verticillin A-Loaded Surgical Buttresses Prevent Local Pancreatic Cancer Recurrence in a Murine Model. · full record | OpenQuestion